ID   G0S2_HUMAN              Reviewed;         103 AA.
AC   P27469; Q6FGC8;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   15-MAR-2017, entry version 118.
DE   RecName: Full=G0/G1 switch protein 2;
DE   AltName: Full=G0/G1 switch regulatory protein 2;
DE   AltName: Full=Putative lymphocyte G0/G1 switch gene;
GN   Name=G0S2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1930693; DOI=10.1089/dna.1991.10.581;
RA   Russell L., Forsdyke D.R.;
RT   "A human putative lymphocyte G0/G1 switch gene containing a CpG-rich
RT   island encodes a small basic protein with the potential to be
RT   phosphorylated.";
RL   DNA Cell Biol. 10:581-591(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, INTERACTION WITH BCL2, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, INDUCTION, AND MUTAGENESIS OF LEU-35; PHE-36; VAL-38;
RP   VAL-39; MET-43; GLU-44; THR-45; VAL-46; PHE-50; THR-51; ARG-54;
RP   ARG-55; ARG-57 AND ASP-58.
RX   PubMed=19706769; DOI=10.1158/0008-5472.CAN-09-0128;
RA   Welch C., Santra M.K., El-Assaad W., Zhu X., Huber W.E., Keys R.A.,
RA   Teodoro J.G., Green M.R.;
RT   "Identification of a protein, G0S2, that lacks Bcl-2 homology domains
RT   and interacts with and antagonizes Bcl-2.";
RL   Cancer Res. 69:6782-6789(2009).
CC   -!- FUNCTION: Promotes apoptosis by binding to BCL2, hence preventing
CC       the formation of protective BCL2-BAX heterodimers.
CC       {ECO:0000269|PubMed:19706769}.
CC   -!- SUBUNIT: Directly interacts with BCL2; this interaction prevents
CC       the formation of the anti-apoptotic BAX-BCL2 complex.
CC       {ECO:0000269|PubMed:19706769}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:19706769}.
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in
CC       peripheral blood, skeletal muscle and heart, followed by kidney
CC       and liver. {ECO:0000269|PubMed:19706769}.
CC   -!- INDUCTION: Induced by TNF through the activation of the NFKB
CC       pathway. {ECO:0000269|PubMed:19706769}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M72885; AAA58966.1; -; Genomic_DNA.
DR   EMBL; M69199; AAB04044.1; -; Genomic_DNA.
DR   EMBL; BT007101; AAP35765.1; -; mRNA.
DR   EMBL; CR542179; CAG46976.1; -; mRNA.
DR   EMBL; CR542193; CAG46990.1; -; mRNA.
DR   EMBL; AL031316; CAB40150.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93447.1; -; Genomic_DNA.
DR   EMBL; BC009694; AAH09694.1; -; mRNA.
DR   CCDS; CCDS1488.1; -.
DR   PIR; B40409; A40409.
DR   RefSeq; NP_056529.1; NM_015714.3.
DR   UniGene; Hs.432132; -.
DR   ProteinModelPortal; P27469; -.
DR   BioGrid; 119073; 1.
DR   IntAct; P27469; 2.
DR   STRING; 9606.ENSP00000355996; -.
DR   PhosphoSitePlus; P27469; -.
DR   BioMuta; G0S2; -.
DR   DMDM; 120624; -.
DR   PaxDb; P27469; -.
DR   PeptideAtlas; P27469; -.
DR   PRIDE; P27469; -.
DR   DNASU; 50486; -.
DR   Ensembl; ENST00000367029; ENSP00000355996; ENSG00000123689.
DR   GeneID; 50486; -.
DR   KEGG; hsa:50486; -.
DR   UCSC; uc001hhi.5; human.
DR   CTD; 50486; -.
DR   DisGeNET; 50486; -.
DR   GeneCards; G0S2; -.
DR   HGNC; HGNC:30229; G0S2.
DR   MIM; 614447; gene.
DR   neXtProt; NX_P27469; -.
DR   OpenTargets; ENSG00000123689; -.
DR   PharmGKB; PA142671707; -.
DR   eggNOG; ENOG410J22N; Eukaryota.
DR   eggNOG; ENOG410YZQR; LUCA.
DR   GeneTree; ENSGT00390000005294; -.
DR   HOGENOM; HOG000112682; -.
DR   HOVERGEN; HBG004465; -.
DR   InParanoid; P27469; -.
DR   OMA; ATLCSRA; -.
DR   OrthoDB; EOG091G14MV; -.
DR   PhylomeDB; P27469; -.
DR   TreeFam; TF336218; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   GenomeRNAi; 50486; -.
DR   PRO; PR:P27469; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000123689; -.
DR   CleanEx; HS_G0S2; -.
DR   Genevisible; P27469; HS.
DR   GO; GO:0005811; C:lipid particle; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR016821; G0S2.
DR   Pfam; PF15103; G0-G1_switch_2; 1.
DR   PIRSF; PIRSF023925; G0/G1_switch_p2; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Complete proteome; Mitochondrion; Reference proteome.
FT   CHAIN         1    103       G0/G1 switch protein 2.
FT                                /FTId=PRO_0000087405.
FT   MUTAGEN      35     35       L->A: No effect on BCL2-binding; when
FT                                associated with A-36.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      36     36       F->A: No effect on BCL2-binding; when
FT                                associated with A-35.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      38     38       V->A: No effect on BCL2-binding; when
FT                                associated with A-39.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      39     39       V->A: No effect on BCL2-binding; when
FT                                associated with A-38.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      43     43       M->A: No effect on BCL2-binding; when
FT                                associated with A-44.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      44     44       E->A: No effect on BCL2-binding; when
FT                                associated with A-43.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      45     45       T->A: No effect on BCL2-binding; when
FT                                associated with A-46.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      46     46       V->A: No effect on BCL2-binding; when
FT                                associated with A-45.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      50     50       F->A: Reduced BCL2-binding; when
FT                                associated with A-51.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      51     51       T->A: Reduced BCL2-binding; when
FT                                associated with A-50.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      54     54       R->A: Reduced BCL2-binding; when
FT                                associated with A-55.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      55     55       R->A: Reduced BCL2-binding; when
FT                                associated with A-54.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      57     57       R->A: Reduced BCL2-binding and reduced
FT                                pro-apoptotic activity; when associated
FT                                with A-58. No effect on mitochondrial
FT                                localization; when associated with A-58.
FT                                {ECO:0000269|PubMed:19706769}.
FT   MUTAGEN      58     58       D->A: Reduced BCL2-binding and reduced
FT                                pro-apoptotic activity; when associated
FT                                with A-57. No effect on mitochondrial
FT                                localization; when associated with A-57.
FT                                {ECO:0000269|PubMed:19706769}.
SQ   SEQUENCE   103 AA;  11321 MW;  0FA91951D419E75C CRC64;
     METVQELIPL AKEMMAQKRK GKMVKLYVLG SVLALFGVVL GLMETVCSPF TAARRLRDQE
     AAVAELQAAL ERQALQKQAL QEKGKQQDTV LGGRALSNRQ HAS
//
